A predisposition for thoracic aortic aneurysms leading to acute aortic dissections can be inherited in families in an autosomal dominant manner. Genome-wide linkage analysis of two large unrelated families with thoracic aortic disease followed by whole-exome sequencing of affected relatives identified causative mutations in TGFB2. These mutations-a frameshift mutation in exon 6 and a nonsense mutation in exon 4-segregated with disease with a combined logarithm of odds (LOD) score of 7.7. Sanger sequencing of 276 probands from families with inherited thoracic aortic disease identified 2 additional TGFB2 mutations. TGFB2 encodes transforming growth factor (TGF)-b2, and the mutations are predicted to cause haploinsufficiency for TGFB2; however, aortic tissue from cases paradoxically shows increased TGF-b2 expression and immunostaining. Thus, haploinsufficiency for TGFB2 predisposes to thoracic aortic disease, suggesting that the initial pathway driving disease is decreased cellular TGF-b2 levels leading to a secondary increase in TGF-b2 production in the diseased aorta.
l e t t e r s family using data from 1,056 microsatellites was performed using samples from 18 family members, and LOD scores of greater than 1.4 were obtained on chromosomes 1, 4, 12 and 20 ( Fig. 1c) . A locus at chromosome 1q41 was shared between the two families. Exome sequencing was pursued in both families using DNA from two distantly related affected individuals (1/16 coefficient of relatedness) from TAA288 and three affected individuals and one unaffected individual from MS239 (circled individuals in Fig. 1a) . Sequencing results were filtered for novel, heterozygous rare variants shared between affected relatives within a family that were nonsynonymous, nonsense or insertion/deletion (indel) variants. This filtering strategy identified 16 rare variants in TAA288 and 5 rare variants in MS239 (Supplementary Table 1 ). Rare variants in TGFB2 were present in both families, and TGFB2 fell within the 1q41 locus that was shown to contain the causative gene in both families (Fig. 1b,c) . The TGFB2 rare variant in TAA288 was a 5-bp deletion (c.1021_1025del-TACAA) in exon 6 of the gene, leading to a frameshift in translation of the transcript and a premature stop codon (p.Tyr341Cysfs*25; Fig. 1d and Supplementary Fig. 1 ). This variant had a two-point linkage LOD score of 3.3 (Θ = 0.0) and was not present in 3,795 control exomes, as determined by bioinformatics analysis and visual inspection of the sequencing data. The TGFB2 variant in MS239 was a nonsense variant in exon 4 (encoding p.Cys229*). Complete segregation with thoracic aortic disease was found in the family with a LOD score of 4.4 (Θ = 0.0). This nonsense rare variant was not present in over 10,000 chromosomes in the Exome Variant Server (EVS) database (see URLs). In fact, there are no TGFB2 rare variants predicted to disrupt translation of the protein in this database (Fig. 1d) . Thus, these data provide strong evidence that the identified TGFB2 mutations are responsible for inherited vascular disease in both families.
To determine the frequency and spectrum of TGFB2 mutations in individuals with thoracic aortic disease, the 7 exons and flanking intronic regions were sequenced using DNA from French probands (62 familial cases and 74 sporadic cases from a Marfan referral clinic) and US probands (214 affected probands in families with 2 or more members with thoracic aortic disease, including 30 families who also had members with intracranial aneurysms and 57 sporadic thoracic aortic disease cases) 7 (Supplementary Table 2 ). Two additional alterations were identified in the French familial cases: a nonsense p.Glu102* alteration in MS1756 and a frameshift duplication (c.873_888dup) leading to the p.Asn297* alteration in MS211; additional family members were not available for analysis (Supplementary Fig. 2) . Therefore, TGFB2 mutations were identified in 2 out of 276 probands with familial thoracic aortic disease. Genome SNP array data for 898 individuals with thoracic aortic disease, including 88 with inherited thoracic aortic disease, were analyzed for genomic rearrangements using CNVPartition and PennCNV, and B-allele frequency and logR ratio files were visually inspected. No deletions or duplications involving TGFB2 were identified 8 .
The TGFB2 nonsense mutations and the frameshift duplication in exon 5 are predicted to lead to degradation of the transcript and to thus cause haploinsufficiency for TGFB2. The mutation identified in TAA288, encoding p.Tyr341Cysfs*25, is a deletion of 5 bp in exon 6, causing a frameshift in protein translation and addition of 25 aberrant amino acids. Because the nonsense codon that terminates protein translation occurs in exon 7, it is not expected to cause nonsensemediated decay 9 . Analysis of the TGFB2 transcript confirmed that similar levels of both mutant and wild-type transcript were present in RNA harvested from aortic tissue and fibroblasts from affected family members (III:11 and IV:1; Fig. 2a and Supplementary Table 2 ). The TGF-β family members are synthesized as peptides that form homodimers cross-linked through disulfide bonds (proprotein), which are cleaved by furin immediately before secretion. TGFB2 expression was similar in SMCs and dermal fibroblasts that were explanted from affected family members in TAA288 and control cells (Fig. 2b) , but immunoblot analysis of the TGF-β2 proprotein in cellular lysates from these cells showed lower amounts of TGF-β2 proprotein in the mutant cells compared to the wild-type ones and provided no evidence of a truncated protein ( Fig. 2c and Supplementary Fig. 3 ). These data suggest that, although the deleted transcript is expressed, the mutant protein is rapidly degraded by an endoplasmic reticulum-associated degradation pathway, resulting in decreased amounts of cellular wildtype TGF-β2.
The aortic pathology associated with TGFB2 mutations was assessed using aortic tissue from subjects MS239 III:16 and MS1756 II:8. The aortic pathology typical for thoracic aortic disease was found, which is characterized by fragmentation and loss of elastin fibers and accumulation of proteoglycans in the tunica media (Fig. 3a) . Assessment of nuclear phosphorylated SMAD2 in medial SMCs from TGFB2-mutant aortas showed greater staining relative to control aortas (Fig. 3b) . TGFB1, TGFB2 and TGFB3 mRNA levels were assessed by quantitative PCR (qPCR) using aortic tissue RNA from III:11 in Figure 2 Transcript and protein analysis of the TGFB2 mutation in exon 6 encoding p.Tyr341Cysfs*25. (a) RT-PCR of RNA extracted from normal ascending aortic specimens (n = 2) or fibroblast cell cultures (n = 2) showed only one PCR product at 160 bp. RT-PCR of RNA extracted from the ascending aorta of an affected individual (III:11) or fibroblast cell culture (IV:1) from family TAA288 showed that the transcript from both the normal allele and an allele with a 5-bp deletion were present. (b) Expression of TGFB2 was quantified in aortic SMCs and dermal fibroblasts explanted from TGFB2 mutation carriers and matched controls (WT) using qPCR. TGFB2 levels were standardized to GAPDH mRNA. Relative expression was determined via the ∆∆C T method, and assays were performed in triplicate. Data are expressed as mean ± s.e.m. for pooled experimental results. (c) Immunoblot analysis of TGF-β2 proprotein in cellular lysates of aortic SMCs and fibroblasts from affected subjects (III:11 and IV:1, TAA288) and two normal controls (WT1 and WT2). A protein band at 47 kDa, the molecular weight of the TGF-β2 proprotein, was identified in lysates from both the affected subjects and controls. Lower intensity of this band was found in cells from affected subjects, both in SMCs and fibroblasts, relative to control cells. , MS1756 ), an aneurysm case (middle) with a TGFB2 mutation resulting in p.Cys229* (III:16, MS239) and a control (WT; right). Hematoxylin and eosin (H&E) staining shows disorganization of the aortic media with loss of SMCs, and Alcian blue staining shows proteoglycan accumulation (blue). Note the loss, disarray and fragmentation of elastin fibers in affected individuals compared to the control with orcein staining. Scale bars, 100 µm. (b) Immunohistofluorescent staining for the same subject and control samples. Elastin fibers appear in green (autofluorescence), and nuclei are counterstained blue. Top, nuclear phosphorylated SMAD2 (p-SMAD2) staining (pink) is present in the disease tissues and is absent in the control aorta. Bottom, intense immunostaining for TGF-β2 (red). Staining for p-SMAD2 and TGF-β2 is located in the most disorganized areas of the aortic wall. Scale bar, 20 µm. (c) Expression of TGFB1, TGFB2 and TGFB3 assayed by qPCR using RNA isolated from the aorta of III:11 from TAA288. Gene expression was standardized to GAPDH. Relative expression was determined via the ∆∆C T method, and assays were performed in triplicate. Data are expressed as mean ± s.e.m. for pooled experimental results. (d) Immunoblot analysis of the mutant and control aortas showed higher levels of the 47-kDa TGF-β2 protein in the affected subject's aorta compared to two control aortas.
npg l e t t e r s family TAA288 and two matched controls (Fig. 3c) . Unexpectedly, only TGFB2 expression was increased in the aortic tissue (Fig. 2b) . Immunoblot analysis of protein lysates from these same aortas showed a corresponding increase in TGF-β2 proprotein levels in the mutant aorta (Fig. 3d) . Immunostaining of TGF-β2 in aortic tissue from subjects MS239 III:16 and MS1756 II:8 also showed higher signal intensity in the affected subjects' aortas compared with control aorta (Fig. 3b) . Thus, the aortas from individuals with TGFB2 mutations show enhanced TGF-β signaling associated with a paradoxical increase in TGFB2 expression and TGF-β2 protein.
The clinical features in TGFB2 mutation carriers were assessed and found to be similar to those in other syndromes causing thoracic aortic disease. The median age at aortic disease presentation was 35 years, with the majority of affected family members presenting with aneurysms at the level of the sinuses of Valsalva (Fig. 4a,b , Table 1 and Supplementary Table 3) . A 60-year-old male underwent surgical repair after his aneurysm enlarged from 47 to 51 mm over 6 years, and a 35-year-old male underwent repair with an aortic root diameter of 54 mm. Aortic dissection was documented in an obligate mutation carrier in MS239 (III:12, female, 56 years old) and in the probands of MS1756 (II:8, male, 47 years old) and MS211 (III:14, male, 31 years old). Three women who were obligate carriers presented with cerebrovascular disease; TAA288-II:1 had a ruptured anterior communicating artery aneurysm at age 54, and TAAII:3 and MS239-III:2 died of SAH, presumably due to ruptured ICAs. Fusiform dilatation and tortuosity of cerebrovascular arteries were present in mutation carriers (Fig. 4c,d) . Additional cardiovascular features included interventricular septal defect present in an obligate carrier from MS239 (III:12), mitral regurgitation requiring surgical repair at the age of 43 years in IV:2 from MS239 and dilated cardiomyopathy before aortic root aneurysm formation in III:3 from TAA288.
Inguinal hernias, typically bilateral and requiring surgical repair, were common in mutation carriers, including women. Skeletal features, joint laxity and skin striae similar to the phenotypes observed in individuals with MFS were found in some individuals with TGFB2 mutations but were insufficient in any individual to meet the diagnostic criteria of MFS (Fig. 4e,f npg l e t t e r s manifestation of the TGFB2 mutation, as similar cerebrovascular disease occurs in individuals with TGFBR1, TGFBR2 or SMAD3 mutations. Lastly, some systemic features overlapping with MFS are also observed, as is the case with other syndromic forms of thoracic aortic disease ( Table 1) 11 . It should be underscored that no aortic dissections occurred in individuals younger than 31 years of age or in those with minimal aortic enlargement. Mice with specific genetic disruption of each of the genes for the three isoforms of TGF-β (Tgfb1, Tgfb2 and Tgfb3) have discrete phenotypes, indicating a distinct role for each of the TGF-β isoforms. Tgfb2-null mice die shortly after birth and have ascending aortas that are comparatively small and thin walled and other development defects involving the heart, lung, craniofacial, limb, spinal column, eye, inner ear and urogenital systems 12 . The developmental processes disrupted by loss of TGF-β2 include the epithelial-to-mesenchymal transition (EMT) and differentiation of neural crest-derived components. Tgfb2-null mice also show dysmorphic calvaria, extensive cleft palate, defective mandibles and retrognathia; only retrognathia was observed in one TGFB2 mutation carrier. On the basis of our findings, haploinsufficiency for TGF-β2 does not disrupt cardiovascular development, suggesting that lower TGF-β2 amounts do not block proper migration or homing of cells during development. Rather, lower amounts of TGF-β2 predispose to adult-onset vascular diseases involving the sinuses of Valsalva and the cerebrovascular arteries. SMCs in these two vascular beds are derived from two different origins, the secondary heart field and neural crest cells, respectively 13 . Thus, the clinical features suggest that lower amounts of TGF-β2 lead to a defect in the differentiation, proliferation or viability of cells in these arteries. The differentiation of neural crest cells into vascular SMCs is dependent on TGF-β signaling, and secondary heart field EMT is specifically TGF-β2 dependent 12, 14 ; lower TGF-β2 amounts may disrupt proper differentiation of SMCs in these arteries. Relevant to this speculation, it is notable that SMCs explanted from individuals with TGFBR2 mutations are relatively dedifferentiated in culture compared to control SMCs and fail to differentiate to the same extent as control SMCs when exposed to TGF-β1 (ref. 15) .
Our results provide evidence that haploinsufficiency for TGFB2 is an initiating step in the pathogenic events leading to thoracic aortic disease. A subset of the SMAD3 mutations results in frameshifts that are predicted to cause SMAD3 haploinsufficiency 16, 17 . The missense mutations in TGFBR1 and TGFBR2 have either been shown to or are predicted to disrupt kinase function, which is critical for propagating TGF-β signaling 4, 15, 16, 18, 19 . Despite the fact that these mutations are predicted to decrease TGF-β signaling, the defective genes trigger poorly understood signaling events that lead to stronger nuclear phosphorylated SMAD2 immunostaining in diseased tissue. Immunostaining for phosphorylated SMAD2 is also stronger in aortas from individuals with thoracic aortic disease without mutations in these genes 5 . One event contributing to stronger staining for phosphorylated SMAD2 may be epigenetic modification of the promoter of SMAD2, resulting in constitutive activation of this signaling protein 20 . Another possible contributing event is that the relative resistance of the SMCs to TGF-β signaling due to the gene mutations may paradoxically increase signaling through other TGF-β signaling proteins. It is notable that deletion of Tgfbr2 in mouse cranial neural crest cells leads to higher expression of TGF-β2 and TGF-β type 3 receptor and activation of SMAD-independent cellular pathways 21 . Our study identified a similar increase in TGF-β2 levels in the diseased tissue in response to TGFB2 haploinsufficiency that is not present in explanted SMCs and fibroblasts. Although our data support the conclusion that the initiating event leading to vascular diseases due to mutations in TGFB2 is lower TGF-β2 levels, further work is warranted to unravel the pathways that are secondarily altered to cause a paradoxical increase in TGFB2 expression and increased signaling by phosphorylated Smad2 in diseased aortic tissue. (Sigma-Aldrich). Membranes were probed with horseradish peroxidaseconjugated secondary antibody (Jackson ImmunoResearch Laboratories, 111-035-045; 1:2,000 dilution). Blots were visualized with enhanced chemiluminescence (Amersham ECL Western Blotting Detection Reagents, GE Healthcare). Densitometry was performed using ImageJ software. Each band was quantified three independent times, and the results shown were pooled from at least two separate immunoblots.
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Statistical analysis of RNA and protein expression. All values are expressed as means ± s.e.m. (s.d. divided by the square root of the number of separate experimental replicates). Statistical differences in t TGFB2 and control RNA levels or in protein expression were analyzed by Student's t tests. Differences were considered statistically significant at values of P < 0.05. Data shown were pooled from at least two experimental replicates.
